Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)

  • End date
    Sep 30, 2023
  • participants needed
  • sponsor
    National Vaccine and Serum Institute, China
Updated on 12 July 2021


Phase II clinical study will explore dose and safety, immunogenicity in 4 age groups, including 18-59 years old group, 6-17 years old group, 3-5 years old group, 6-35 months old group, with a total of 1716 subjects.

Condition Norwalk Gastroenteritis, Norovirus Infections
Treatment Placebo, low-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine, high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine
Clinical Study IdentifierNCT04941261
SponsorNational Vaccine and Serum Institute, China
Last Modified on12 July 2021


Yes No Not Sure

Inclusion Criteria

Age range: healthy people aged 6 months -59 years and and older who can provide legal identification
Inquired about medical history and physical examination, the investigator judged that the health condition is good
The subject and/or his legal guardian and/or his entrusted person can understand the study procedures and informed consent, voluntarily sign informed consent form, and be able to comply with the requirements of the clinical study protocol
Females of childbearing age (menarche to menopause) are not pregnant at the time of enrollment (negative urine pregnancy test), not breastfeeding, and have no birth plan within 12 months after enrollment; effective contraception will be taken within 2 weeks before enrollment

Exclusion Criteria

First Dose Exclusion Criteria
Axillary body temperature is not less than 37.3 (older than 14 years) before vaccination, and axillary body temperature is not less than 37.5 (14 years or younger) before vaccination
Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc
Have received immune enhancement or inhibitor therapy within 3 months (continuous oral or instillation for more than 14 days)
Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases
Having serious congenital malformations or chronic diseases (including but not limited to:Down syndrome, thalassemia, heart disease, kidney disease, diabetes, autoimmune disease, genetic allergies, Guillain Barre syndrome, etc.)
Asthenia or splenectomy, functional asthenia caused by any situation
Severe liver and kidney disease, severe cardiovascular disease, drug-uncontrollable hypertension (systolic blood pressure is not less than 140mmHg, diastolic blood pressure is not less than 90mmHg), high blood glucose, diabetic complications , Malignant tumors, various acute diseases or acute attacks of chronic diseases
Have a history of chronic gastrointestinal disease, current diarrhea or other digestive system diseases, gastroenteritis requiring treatment in the past 7 days
Have a history of abnormal coagulation function (such as coagulation factor deficiency, coagulopathy)
Have a history of severe allergic reactions to vaccination; allergic to any component of the experimental vaccine
Have received a live attenuated vaccine within 28 days before vaccination, or received other vaccinesRecombinant vaccine, subunit vaccine, inactivated vaccine within 14 days before vaccination
Received within 6 months before vaccination or plan to receive other study drugs in the near future
Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit; Other conditions considered by the investigator to be inappropriate for participation in the study
In addition to the general exclusion criteria, specific populations should
also follow the following exclusion criteria
Children aged 24 months and under are born prematurely (delivered before the 37th week of pregnancy), low-weight (birth weight for girls <2300g, boys <2500g) infants; Children 24 months of age and younger have a history of dystocia, birth asphyxia or other reasons, a history of neurological damage, severe chronic diseases (such as Down syndrome, sickle cell anemia, or neurological disorders)
Subsequent doses of vaccination Exclusion criteria
Have a high fever (axillary temperature is not less than 39.0) for three days and severe allergic reaction after the previous dose of vaccination
Severe adverse reactions that are causally related to the previous dose of vaccination
For those newly discovered or newly identified after the previous dose of vaccine that does not meet the first dose selection criteria or meets the first dose exclusion criteria, the investigator will determine whether to continue participating in the study
Other exclusion reasons considered by the investigator
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note